Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Casetta

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
International Journal of Surgical Pathology|August 13, 2004
Prostatic duct carcinoma with combined prostatic duct adenocarcinoma and urothelial carcinoma features: report of a caseD Pacchioni, G Casetta, M Piovano, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Immunohistochemical evaluation of the safety of transurethral electrovaporization of the prostate and its clinical resultsA Tizzani, P Gontero, G Casetta, et al.
European Urology|August 15, 2000
Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladderP Gontero, G Casetta, A Zitella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markersC F Sier, G Casetta, J H Verheijen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 6, 1998
White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control studyM Peluso, L Airoldi, M Armelle, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 16, 2001
Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancerG Priolo, P Gontero, G Martinasso, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 23, 1999
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevanceC F Sier, N Sidenius, A Mariani, et al.
Urologia Internationalis|October 12, 2000
BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladderG Casetta, P Gontero, A Zitella, et al.
British Journal of Cancer|January 8, 2004
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancerW Albrecht, H Van Poppel, S Horenblas, et al.
Urologia Internationalis|August 30, 2014
The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcomeM Racioppi, L Salmaso, C Brombin, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
International Journal of Surgical Pathology|August 13, 2004
Prostatic duct carcinoma with combined prostatic duct adenocarcinoma and urothelial carcinoma features: report of a caseD Pacchioni, G Casetta, M Piovano, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Immunohistochemical evaluation of the safety of transurethral electrovaporization of the prostate and its clinical resultsA Tizzani, P Gontero, G Casetta, et al.
European Urology|August 15, 2000
Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladderP Gontero, G Casetta, A Zitella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markersC F Sier, G Casetta, J H Verheijen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 6, 1998
White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control studyM Peluso, L Airoldi, M Armelle, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 16, 2001
Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancerG Priolo, P Gontero, G Martinasso, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 23, 1999
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevanceC F Sier, N Sidenius, A Mariani, et al.
Urologia Internationalis|October 12, 2000
BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladderG Casetta, P Gontero, A Zitella, et al.
British Journal of Cancer|January 8, 2004
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancerW Albrecht, H Van Poppel, S Horenblas, et al.
Urologia Internationalis|August 30, 2014
The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcomeM Racioppi, L Salmaso, C Brombin, et al.
Pageof 4